PPARG and metabolic dysfunction-associated steatotic liver disease: Nevertheless, reduction of fructose should be recommended for patients with NAFLD along with emerging therapies that can lower the activity of liver enzymes, fibrosis, and inflammation, such as PPARγ inhibitors (pioglitazone), SGLT-2i, and GLP-1 RA, as well as modification in gut microbiota.